← Back to news

· 6 min read · LONGEVITY LEAK

Supplement Cycling Protocols: Rapamycin, Senolytics, and Adaptogens — Evidence for Intermittent Use

Not all supplements should be taken daily. Rapamycin is typically dosed weekly to preserve mTOR signaling windows. Senolytics (dasatinib + quercetin, fisetin) are used in short intermittent bursts. Even some adaptogens are cycled to prevent tolerance. This article maps the rationale and evidence for each.

Clinical Brief

Source
Peer-reviewed Clinical Study
Published
Primary Topic
supplement-cycling
Reading Time
6 min read

Evidence and Risk Labels

Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.

See full scoring guide

The default assumption in supplement use is daily, continuous administration. For most supplements — vitamins, minerals, fish oil, creatine — this is appropriate. But for a growing category of longevity-focused compounds, the mechanism of action itself demands intermittent use. Continuous administration of these agents either causes tolerance, blocks beneficial physiological processes, or requires accumulation of a triggering condition (like senescent cells) before the intervention is effective.

This article covers the three main categories where cycling has the clearest mechanistic and evidence-based rationale: mTOR inhibitors (rapamycin), senolytics, and adaptogens.

Rapamycin: Weekly Dosing and mTOR Biology

Rapamycin is an mTOR (mechanistic target of rapamycin) inhibitor originally developed as an immunosuppressant for organ transplantation. At low, intermittent doses, it has produced consistent lifespan extension in multiple model organisms — most dramatically in the Interventions Testing Program (ITP) mouse studies, where rapamycin extended median lifespan by 14-38% in both male and female mice, even when started in old age (equivalent to starting in a human in their 60s).

The mechanistic rationale for weekly rather than daily dosing is important: mTORC1 inhibition reduces anabolic signaling, which suppresses cellular protein synthesis and promotes autophagy — both longevity-associated effects. However, mTOR is also required for immune function, muscle protein synthesis, and wound healing. Daily rapamycin at transplant doses produces immunosuppression and metabolic side effects. Weekly low-dose rapamycin (typically 1-8 mg once weekly in current self-experimentation protocols) attempts to transiently inhibit mTOR to capture the autophagy and senescence-clearing signal while allowing adequate mTOR signaling recovery during the remaining days.

The PEARL trial (Program to Evaluate Aging in Longevity trial) in 210 community-dwelling adults over 50 found that weekly rapamycin (5 mg) was generally well tolerated over 48 weeks, with modest improvements in physical function measures. This is the first adequately powered safety and tolerability RCT in healthy older adults. Efficacy data for longevity endpoints require much longer follow-up.

Important: rapamycin is a prescription medication. Self-administration without medical supervision carries real risks including impaired immune response, oral ulcers, hyperlipidemia, and impaired wound healing. The longevity dosing rationale is mechanistically sound but not established in formal clinical trials for this indication.

Senolytics: Burst Dosing for Cellular Clearance

Cellular senescence is a hallmark of aging. Senescent cells — cells that have irreversibly stopped dividing but have not died — accumulate with age and secrete a pro-inflammatory signaling cocktail (the SASP: senescence-associated secretory phenotype) that promotes tissue dysfunction, chronic inflammation, and neighboring cell dysfunction. Senolytic drugs selectively induce apoptosis in senescent cells.

The burst dosing rationale for senolytics is mechanistic: senescent cells accumulate over months, are cleared during a senolytic burst, then gradually re-accumulate. There is no benefit to daily administration because the target cells are cleared in days and the cycle of re-accumulation takes weeks to months.

Dasatinib + quercetin (D+Q): The first validated senolytic combination in humans. Mayo Clinic Phase 1 and Phase 2 trials demonstrated safety and reduction in circulating senescent cell burden, senescence-associated secretory phenotype markers, and physical function improvement in patients with idiopathic pulmonary fibrosis (IPF). The studied dosing regimen is 3 consecutive days of dasatinib (100mg/day) + quercetin (1000mg/day), repeated every 2-4 weeks. Dasatinib is a prescription chemotherapy drug with significant side effects; this protocol is not appropriate for self-administration.

Fisetin: A naturally occurring flavonoid found in strawberries, apples, and onions. Mayo Clinic preclinical data showed fisetin reduced senescent cell burden in aged mice and extended healthspan. A 2023 pilot trial in 40 older adults with mild cognitive impairment found a high-dose intermittent protocol (20mg/kg/day for 2 consecutive days, repeated monthly for 6 months) was well-tolerated and improved some cognitive measures. Dose is substantially higher than typical supplement dosing. Continuous daily supplementation at lower doses (100-500mg) is how most people use fisetin as a general antioxidant; this is different from the senolytic protocol and has not been validated for senescent cell clearance.

Quercetin: Sold widely as a supplement for immune support. At senolytic doses (1000mg/day for several consecutive days), quercetin has separate potential effects on autophagy and senescence. At typical antioxidant supplement doses (200-500mg/day), the mechanism of action is primarily anti-inflammatory rather than senolytic.

Adaptogen Cycling: Tolerance and HPA-Axis Considerations

The rationale for cycling adaptogens (ashwagandha, rhodiola, eleuthero) is less mechanistically rigorous than for rapamycin or senolytics, but there is some biological reasoning: repeated activation of the same stress-adaptive pathways may produce receptor downregulation and diminished response over time.

Evidence for adaptogen tolerance is largely anecdotal and based on traditional use protocols. There are no published tolerance studies with continuous versus intermittent ashwagandha use. What clinical trials do show is that ashwagandha's cortisol-lowering and testosterone effects are well demonstrated over 8-12 weeks — the period most trials assess. What happens beyond 12 weeks with continuous use is not characterized.

Common cycling conventions in practice:

  • Ashwagandha: 8-12 weeks on, 4 weeks off
  • Rhodiola: 6-8 weeks on, 2-4 weeks off (some traditional protocols suggest 5 days on, 2 days off)
  • Eleuthero (Siberian ginseng): 6-8 weeks on, 2-4 weeks off

These conventions are reasonable from a mechanistic standpoint but should be understood as pragmatic rather than evidence-established.

What Should Be Taken Continuously

For contrast: the following supplements have no evidence for tolerance and strong rationale for continuous use:

  • Vitamin D3 and K2: nutrient repletion, not receptor-dependent
  • Omega-3 fatty acids: structural membrane incorporation requires consistent intake
  • Creatine: muscle saturation requires maintenance; returns to baseline after cessation
  • Magnesium: daily mineral requirement that is chronically under-supplied by typical Western diet
  • Folate, B12: continuous metabolic requirement

The distinction is between supplements that act as nutrients (require consistent intake to maintain status) versus supplements that produce pharmacological effects on signaling pathways (where tolerance or context-dependence may apply).

Related pages: Rapamycin, Fisetin, Ashwagandha, Biological Aging Rate, Rapamycin Pearl Trial Women Benefits, Fisetin Removes Zombie Cells Mayo Clinic

Evidence Limits and What We Still Need

Cycling protocols for longevity-focused compounds are largely extrapolated from mechanistic reasoning, animal studies, and small Phase 1-2 human trials. No long-term RCT has compared continuous versus intermittent dosing for any of these compounds with longevity or functional aging endpoints. The optimal senolytic cycle frequency — how often to administer D+Q or fisetin — has not been determined in humans. Rapamycin's long-term effects on immune function, wound healing, and metabolic parameters at longevity doses are not characterized beyond 48 weeks. Adaptogen tolerance is entirely theoretical; the clinical significance of cycling versus continuous use has never been compared in a trial. The field urgently needs multi-year, adequately powered trials with hard endpoints.

Sources

  1. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009. https://pubmed.ncbi.nlm.nih.gov/19587680/
  2. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014. https://pubmed.ncbi.nlm.nih.gov/25399093/
  3. Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018. https://pubmed.ncbi.nlm.nih.gov/29988130/
  4. Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/31227356/
  5. Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. https://pubmed.ncbi.nlm.nih.gov/30279143/
  6. Kulkarni AS, et al. Reprogramming cardiometabolic health with rapamycin for longevity. J Clin Invest. 2020. https://pubmed.ncbi.nlm.nih.gov/31627717/

Source Documentation

Access the original full-text paper for deeper clinical validation.

Read Full Study →

Further Reading

Get the next leak.

Join 1,988+ readers getting the latest longevity research weekly.